• Alexo Therapeutics marks next significant milestone by initiating ALX148 combination cohorts

    2 days ago - By News Medical

    Alexo Therapeutics, a clinical-stage immuno-oncology company developing therapies to block the CD47 checkpoint mechanism, today announced it has initiated ALX148 combination dosing with targeted antibody therapies in its Phase 1 clinical program in patients with advanced solid tumors and lymphoma.
    Read more ...